CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present on its identification and validation of a novel fetal hemoglobin repressor in an oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting taking place December 7-10 in Orlando, Florida. The finding, which is part of Syros’ broader drug discovery effort in sickle cell disease, will also be highlighted in an ASH press briefing.
Details of the oral presentation and press briefing are below:
Oral Presentation
Presentation Title: Chromatin Accessibility Mapping of Primary Erythroid Cell Populations Leads to Identification and Validation of Nuclear Factor I X (NFIX) As a Novel Fetal Hemoglobin (HbF) Repressor
Session Date & Time: Monday, December 9, 4:30 p.m. – 6:30 p.m. ET
Presentation Time: 4:45 p.m. ET
Session Title: Thalassemia and Globin Gene Regulation: Hemoglobin Regulation and Beta Thalassemia Research
Presenter: Mudit Chaand, Ph.D., Syros
Abstract Number: 124337
Location: Orange County Convention Center, Valencia A (W415A)
Press Briefing
Topic: Sickle Cell Disease
Date and Time: Sunday, December 8, 2019, 8:00 a.m. – 9:00 p.m. ET
Presenter: Jeff Shearstone, Ph.D., Syros
Location: ASH Press Briefing Room: Orange County Convention Center, West Building, Level 1 (W221DE)
The abstract is now available online on the ASH website at http://www.hematology.org/Annual-Meeting/.
About Syros Pharmaceuticals:
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline of development candidates, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in investigational new drug application-enabling studies in cancer. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases, including sickle cell disease. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005034/en/
Media Contact:
Naomi Aoki
Syros Pharmaceuticals, Inc.
617-283-4298
naoki@syros.com
Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Source: Syros Pharmaceuticals, Inc.
Released November 6, 2019